Vivus/KV EvaMist approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Vivus' metered-dose topical estradiol spray EvaMist to treat moderate to severe vasomotor symptoms due to menopause. The July 27 approval triggers a $140 million payment to Vivus from KV Pharmaceutical, which will market the drug with its more than 280-strong sales force. Vivus received a $10 million up-front payment and is eligible to get more money based on sales milestones. The firm is touting EvaMist's safety profile, but will be competing in a crowded transdermal estradiol market with close competitors Esprit Pharma's Estrasorb, Ascend's EstroGel and BioSante's Elestrin. Vivus is also developing an obesity combo agent, Qnexa (1Pharmaceutical Approvals Monthly September 2006, p. 11)...
You may also be interested in...
Vivus Plans Evamist NDA In Q4 2006, But Obesity Combo Qnexa Is Top Priority
While Vivus is getting ready to submit its NDA for Evamist early in the fourth quarter of 2006, the company is calling its obesity drug Qnexa a potential blockbuster and earmarking it as its top priority.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.